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1. Introduction 
Every year an estimated two million people die of advanced liver disease. The World Health 
Organization estimates that over six hundred and fifty million people worldwide are 
affected by some form of liver disease, including thirty million Americans. On a worldwide 
base, the bleak cenario of one to two million deaths are accounted to liver related diseases 
annually. From all the countries, China has the world’s largest population of Hepatitis B 
patients (approx. 120 million) with five hundred thousand people dying of the liver disease 
every year(1, 2). In the US alone, there are around five hundred thousand critical episodes of 
liver problems every year requiring hospitalization with a huge burden to the patients and 
an enormous cost to the health care system. In the European Union and United States of 
America alone, over eighty one thousand and twenty six thousand people died of chronic 
liver disease in 2006, respectively(1, 3). For these patients, liver transplantation is currently 
the only therapy proven to extend survival for end-stage liver disease, as it is also the only 
treatment for severe acute liver failure and the some forms of inborn errors of metabolism. 
However, the waiting list for liver transplants is extensive and many on the list will not 
receive an organ due to a dramatic shortage of donors or not being eligible(1).  
A good example of this is that in 2007 there were nearly seventeen thousand individuals on 
the US waiting list for a liver transplant. Only 30% of those in need were transplanted. The 
average waiting time was more than 400 days. The same year, about one thousand and three 
hundred people died while waiting for a suitable donor with no available medical option for 
saving their life. Also, for those patients with fulminant hepatic failure, a severe liver disease 
with 60-90% mortality, depending on the cause, only 10% received a transplant. 
Nevertheless, liver transplantation still has a relatively high mortality of 30-40% at 5-8 years 
with 65% of the deaths occurring in the first 6 months. In addition, patients who have 
undergone transplantation have to use lifelong immunosuppressive therapy, with 
sometimes severe side effects(4). 
The etiologies of end-stage chronic liver disease that lead to transplantation are numerous 
and ~80% of people in the liver transplant waiting list have as primary diagnosis a cirrhotic 
liver. Fortunately, some of the causes of the disease are nowadays preventable. A good 
example is the successful vaccination programs in many countries in the world against 
Hepatitis B virus that have considerably reduced the incidence of chronic carriers and viral 
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induced cirrhosis(5). Regrettably, close to 20% of the livers transplanted in the USA and 30% 
in Europe have a preventable underlying cause, alcoholic liver disease. Also ~45% of deaths 
due to liver cirrhosis in the USA are related with alcohol abuse(1, 3, 4). Patients with 
pathologies like hepatic cancer, congenital malformations and metabolic diseases, and acute 
hepatic necrosis compose the remaining percentage of the list. 
2. Transplantation 
The success of liver transplantation has resulted in a progressively increasing demand for 
such treatment. However, as mentioned above, at the same time the availability of donor 
organs has diminished, resulting in the number of potential recipients for liver 
transplantation far exceeding organ supply. Given this, several strategies have been 
explored in the last decade or so with the aim to increase access to liver transplantation. 
These include obtaining organs from non-heart-beating donors and live donors, and 
splitting and using livers from expanded donor criteria. Also, the introduction of the Model 
for End-Stage Liver Disease (MELD) system implemented February 27 of 2002 in the United 
States helped Organ Procurement Organizations to prioritize patients waiting for a liver 
transplant. The MELD score is a numerical scale used for adult liver transplant candidates 
that ranges between 6 (less ill) and 40 (gravely ill). The individual score determines how 
urgently a patient needs a liver transplant within the next 3 months. The number is 
calculated using the most recent laboratory tests – table 1(6). 
 
Bilirubin which measures how effectively the liver excretes bile 
INR formally known as the prothrombin time, measures the liver’s ability to 
make blood clotting factors 
Creatinine which measures kidney function. Impaired kidney function is often
associated with severe liver disease 
Table 1. Laboratory values used in the MELD score calculation 
The MELD score is then distributed in 4 levels according with the severety of the disease. 
Less than or equal to 10, 11-18, 19-24 and greater than or equal to 25, being the last the level 
that includes the most severe patients. Nevertheless, MELD score is not the only factor used 
for organ allocation to a patient. 
In general, for organ distribution a donor is matched to a potential recipient on the basis of 
several factors: ABO blood type, body size, degree of medical urgency and MELD score. 
Organ Procurement Organizations (e.g. OPTN/UNOS, etc) uses a computerized point 
system to distribute organs in a fair manner. Recipients are chosen primarily on the basis of 
medical urgency within each ABO blood group. Waiting time is only a factor when patients 
have the same MELD score. 
Nevertheless, there are four Special Case Exceptions that will be assigned a higher MELD 
score than that assigned by the patient’s laboratory test results:  
• Hepatocellular Carcinoma 
• Hepatopulmonary Syndrome 
• Familial Amyloidosis 
• Primary Oxaluria 
www.intechopen.com
 
Liver Regeneration and Bioengineering – The Emergence of Whole Organ Scaffolds 
 
243 
In addition to the previously mentioned four special case exceptions, a transplant center can 
apply for a MELD exception for a patient whose medical urgency is not reflected by the 
MELD score(6). 
The implementation of more fair and efficient allocation systems, improvement in the 
immunosupressive regimens, and the increase of living donation have all helped to increase 
overall patient survival and graft survival in the past decade in the United States. The 
number of livers transplanted also increased to a all time high in 2006, with a marked 
decrease on the waiting time for liver transplantation after MELD implementation, 
especially for the sickest patients. 
An example of the impact of these improvements is the increase of 6% (86% in 2007) and 
16% (87% in 2007) of the unadjusted 1-year graft survival for deceased donor and living 
donor liver recipients between 1998 and 2007, respectively. These accounts also for an 
improvement of 3% (89% in 2007) and 11% (91% in 2007) of the unadjusted 1-year patient 
survival for deceased donor and living donor liver recipients for the same period, 
respectively(7). However, these numbers decrease significantly for the 5-year patient survival. 
In 2007 it was 74% and 79% for deceased donor and living donor liver recipients, respectively. 
These numbers decrease even further for the 10-year patient survival, where in 2007 we had 
61% and 71% patient survival for deceased donor and living donor liver recipients, 
respectively. One important note is that patient survival was higher than graft survival ~5%, 
because of the opportunity for repeat liver transplantation in the event of graft failure(8). 
These numbers highlight the need for novel therapies that can increase patient survival, as 
well as lower costs to the health care systems. Tolerance research and its clinical induction is 
a good example of this. The identification of molecular signatures in tolerant patients in 
whom immunosuppression could be stopped, and induction of tolerance, through 
lymphocyte depletion or T lymphocyte co-stimulation blockade, are the most advanced 
approaches to reduce complications of immunosuppression(9). 
3. Bioartificil liver devices 
In the past few decades, due to scarcity of donors, extracorporeal liver support devices have 
been developed to support the failing liver resulting from different complications. These 
devices were created initially for the management of patients waiting for a suitable donor 
for orthotopic liver transplantation. Recent advances in the design of these devices allow 
now utilizing them in the recovery of the native liver from an acute injury. Thus, these 
devices can either bridge the patients to liver transplantation or can fully avoid the need for 
it (10). Liver support devices can be broadly classified into two classes: artificial liver (AL) 
devices and bioartificial (BAL) devices. The artificial support devices are designed to 
detoxify the blood or plasma via different methods like hemodialysis, hemofiltration, 
hemodiafiltration, hemadsorption, plasmapheresis, plasma fractionation and albumin 
dialysis (10, 11). Bioartificial support devices are targeted towards providing essential 
metabolic and synthetic functions of liver along with removal of toxins. BAL devices 
generally utilize primary hepatocytes or hepatoma cell lines incorporated into a bioreactor 
system to perform the essential liver functions (12). Here, we will discuss the operating 
principles of several artificial and bioartificial support systems which have been or are 
currently used in clinical trials.  
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3.1 Artificial liver devices 
Various metabolic functions of the liver are severely impaired during acute or chronic liver 
failure which leads to accumulation of lethal toxins in the body. ALs were developed as 
support devices which can efficiently remove these toxins from blood or plasma by using 
membrane filtration and/or adsorbents. Liver Dialysis device, Molecular Adsorbent 
Recirculating System (MARS) and Prometheus are the most widely used artificial support 
systems.  
In liver dialysis device the patient’s blood is drawn from a central vein and passed through 
a low-to-medium permeability membrane and at the same time a suspension of powdered 
activated charcoal and cation exchange resin is pumped through the dialysate side of the 
dialyser. This result in removal of toxins from the blood as the toxins are adsorbed based on 
their binding affinities (10, 13). The MARS uses an albumin-impermeable membrane (50 kDa 
cutoff) which separates the high-flux albumin coated dialyser from albumin filled dialysate. 
The toxins bound to the albumin are dissolved from the patient’s albumin and they pass 
through the membrane and ultimately bind to the albumin solution in dialysate side. This 
albumin is then recycled by dialysis or adsorption through charcoal and resin-binding 
columns (14, 15). Prometheus primarily uses fractional plasma separation and adsorption 
techniques for removal of toxins. It uses an albumin permeable membrane (250 kDa cutoff) 
in contrast to MARS. The albumin bound toxins passes through the membrane and passes 
through special adsorbers which directly remove the toxins from the plasma and delivering 
the free albumin back to the patient (13, 14). 
Liver Dialysis, MARS and Prometheus have been widely used in clinical trials across Europe 
and Asia, and have showed some benefits to the patients but no major outcome benefits as 
far as patient survival is concerned. 
3.2 Bioartificial liver devices 
Although ALs have been shown to provide temporary support to the patients with acute 
liver failure by detoxifying the blood or plasma, they have major limitations in replacing 
synthetic and metabolic functions of liver (12). Thus, attempts have been made to develop 
bioartificial liver (BAL) systems, which can provide both metabolic and synthetic hepatic 
functions and its detoxification. BALs incorporate primary hepatocytes or hepatoma cell 
lines as a biological component and hollow fiber or porous matrix membranes on which the 
functional hepatocytes are coated (12, 16). Many cell types from various sources have been 
investigated for providing bioartificial liver support. Primary human hepatocytes have been 
widely studied as an ideal cell source due to their biocompatibility but they are not readily 
available and their proliferative capacity in vitro is limited (13, 16). Animal cell source such 
as porcine primary hepatocytes are being investigated due to ease of availability and their 
ability to maintain metabolic functions similar to human hepatocytes. However, concerns 
regarding immunological reaction to the animal proteins and transmission of disease exist 
(17). Nonetheless, porcine hepatocytes remain a popular choice as a hepatocyte source in 
various BAL systems. 
A bioreactor is a vital component of BALs and it has a major influence on the efficacy of 
these systems. In order to be used in BAL systems, the bioreactor should be able to provide a 
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suitable environment for hepatic cells to thrive and remain functional along with an 
adequate interface between blood and hepatocytes for mass transport (18). The bioreactors 
should also have a potential for scale up and flexibility as BALs may be required to be 
customized to the patient’s needs. Thus, there is an inevitable need for structural 
optimization and modifications of the bioreactors even though there have been recent 
advances in this technology. It should be highlighted that no bioreactor is currently 
approved for patient use, although some have been used in clinical trials (19). Here is a list 
of BAL devices currently under clinical investigation: 
1. Extracorporeal Liver Assist Device (ELAD) 
2. HepatAssist 
3. Bioartificial Liver Support System (BLSS) 
4. The Academic Medical Center – Bioartificial Liver (AMC-BAL) 
5. Modular Extracorporeal Liver Support device (MELS) 
So far over 200 patients have been treated with HepatAssist and over 40 patients treated 
with ELAD, making them the most common BALs used for treatment (15, 20). ELAD is the 
only BAL system which uses human hepatocyte cell line. The other BAL systems listed 
above use porcine hepatocytes as a cell source. ELAD uses immortalized C3A cell line 
derived from human hepatoma cell line HepG2 (21). The cells are located in the 
extracapillary space of hollow fibre cartridges (200 gram total cells in four cartridges). The 
membrane is impermeable to immunoglobulins, blood cells and C3A cells. The blood flows 
through the lumen of cartridges as the ultrafiltrated plasma from the membrane comes in 
direct contact with hepatocytes (12). HepatAssist incorporates approximately 5-7 billion 
cryopreserved porcine hepatocytes attached to microcarriers and loaded onto a hollow fibre. 
The separated plasma passes through a charcoal column and oxygenator prior to entering 
the hollow fibres in the bioreactor. An upgraded version of HepatAssist contains 15-20 
billion porcine hepatocytes. The membrane pores are 0.15µm in size which prevents a 
physical contact between human cells and porcine hepatocytes (10, 20). Currently, none of 
the BALs have been approved by FDA for clinical use. All of the above listed BALs are 
undergoing several clinical trials in USA and Europe. 
3.3 Future of liver support devices 
Recent developments in artificial and bioartificial devices have shown a promising path 
towards the management of patients with acute liver failure. However, considerable 
technical challenges and regulatory issues remain to be tackled in order to efficiently utilize 
these devices in the clinic. ALs have demonstrated the ease of use and cost effectiveness 
along with proving to improve biochemical parameters and clinical symptoms by 
detoxifying the blood/plasma, but it has a major limitation of not replacing critical 
metabolic and synthetic functions of liver. In order to ameliorate liver injury and 
subsequently prevent the lethal effects of loss of liver function on other critical organs, liver 
function needs to be performed by the extracorporeal support devices while the patient 
awaits the transplantation. BALs have been developed in recent years which utilize 
hepatocytes in a bioreactor to carry out the metabolic and synthetic functions of liver. For 
these reasons, BALs hold a promising future as they have shown potential by efficiently 
treating several patients across different clinical trials. Several challenges exist in BAL 
technology including the debate on ideal cell source, requirement of large number of cells, 
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maintainance of the functional hepatocytes for longer period of time in a bioreactor, 
complexity of the design and high cost. These challenges have delayed the entry of BAL 
systems in the clinic. Nonetheless, plenty of optimized designs of liver support devices are 
under development and undergoing clinical trials which is a sign of optimism in this area of 
critical care and management. 
4. Cell therapies 
Hepatocyte transplantation is certainly in the forefront of new therapeutic strategies. The 
first successful hepatocyte transplantation into a patient was carried out in June 1992 to a 
French Canadian woman with familial hypercholesterolaemia. After ex vivo transduction 
with a retrovirus encoding for the human LDL receptor, the patient’s hepatocytes were 
infused through the inferior mesenteric vein into the liver. LDL and HDL levels improved 
throughout the next 18 months and transgene expression was detected in a liver biopsy(22). 
Following this first success, other patients followed through. However, not all the patients 
treated had a clear benefit from the procedure(23). Since then, several other metabolic 
diseases have been treated with hepatocyte transplantation with different degrees of 
success(24-28). It has also been used as a support treatment to acute(29-31) and chronic liver 
diseases(30-33) in bridging severely ill patients to orthotopic liver transplantation (OLT). 
Low efficacy and lack of long-term therapeutic effect have been common in all these 
procedures. These failures could be explained by the relatively small number of hepatocytes 
that engraft in the recipient liver due to quality, quantity and possibly immunosuppresion 
protocols(34). However, transplantation of a number of hepatocytes corresponding to 1-5% 
of the total liver mass has been able to show a positive impact in transplanted patients, even 
if for a limited period of time(34). 
Due to the shortage of available human hepatocytes for transplantation, other cell sources 
have been used. Specifically, bone marrow derived mesenchymal stem cells(35), 
hematopoietic stem cells(36, 37) and fetal liver progenitor/stem cells(38) have shown to 
improve, to a certain extent, the condition of cirrhotic patients. The latter cell type  holds an 
enormous potential for cell/regenerative medicine therapies due to their high expansion 
capabilities  and differentiation into hepatocytes and biliary epithelium(39). 
Recent data suggests that human embrionic (hES) and induced pluripotent (iPS) stem cells 
hold great promise to regenerative applications in every medical field. Specifically for the 
liver, several studies have established the required pathways to differentiate a hES or iPS 
into a hepatic fate by using defined soluble growth factor signals that mimic embryonic 
development(40, 41). These cells, once transplanted into rodent livers were able to engraft 
and express several normal hepatic functions(42). However, more extensive 
characterization, as well as further safety evaluation, are needed  to determine wether these 
cells will fully function as primary adult hepatocytes. 
5. Liver bioengineering 
Tissue engineering is one of the most promising fields in regenerative medicine. As 
described in 1993 by Robert Langer and Joseph Vacanti it is the conjugation of biomaterials 
(synthetic or naturally derived) with cells, in order to generate tissue constructs that can be 
implanted into patients to substitute a lost function, maintain or gain new functions(43). The 
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current paradigm is suitable for the engineering of thin constructs like the bladder, skin or 
blood vessels. Although, in the specific case of the liver, the 3D architecture and dense 
cellular mass requires novel tissue engineering approaches and the development of 
vascularized biomaterials, in order to support thick tissue masses and be readily 
transplantable. Additionally to the vascular support for large tissue masses, hepatocyte 
function maintenance represents the ultimate aim in any organ engineering or regenerative 
medicine strategy for liver disease. 
Hepatocytes are known to be attachment-dependent cells and lose rather quickly their 
specific functions without optimal media- and ECM- composition and cell-cell contacts. 
Also, function and differentiation of liver cells are influenced by the 3D organ 
architecture(44). 
In the last two decades innumerous strategies for the culture of adult hepatocytes in 
combination with several types of 3D, highly porous polymeric matrices have been 
attempted(45-49). However, in the absence of vasculature, restriction in cell growth and 
function is common due to the limitations in nutrient and oxygen diffusion. Some of these 
problems are being now partially overcome with the development of bioreactors that 
provide continuous perfusion of culture media and gases allowing a 3D culture 
configuration and hepatocyte function maintenance(50-52). 
The tissue engineering concept has several advantages over the injection of cell suspensions 
into solid organs. The matrices provide sufficient volume for the transplantation of an 
adequate cell mass up to whole-organ equivalents45. Transplantation efficiency could readily 
be improved by optimizing the microarchitecture and composition of the matrices as well as 
by attaching growth factors and extracellular matrix molecules to the polymeric scaffold, 
helping to recreate the hepatic microenvironment(44). The use of naturally derived matrices 
has also proved to be very helpful in hepatocyte culture(47). These matrices, besides 
preserving some of the microarchitecture features of the tissues that they are derived from, 
also retain bioactive signals (e.g., cell-adhesion peptides and growth factors) required for the 
retention of tissue-specific gene expression(53, 54). Additionally, cell transplantation into 
polymeric matrices is, in contrast to cell injection into tissues and organs, a reversible 
procedure since the cell-matrix-constructs may be removed if necessary. 
Finally, heterotopic hepatocyte transplantation in matrices has already been demonstrated 
in long-term studies(55, 56). Nonetheless, initial engraftment rates are suboptimal. One of 
the reasons for this is the absolute requirement of the transplanted hepatocytes for 
hepatotrophic factors that the liver constantly receives through its portal circulation(57). 
Thus, the development of a tissue engineered liver construct capable of being orthotopically 
transplanted is essential. 
Apart from cellular therapies, other early developments of experimental approaches are not 
showing results that will indicate clinical translation in the next few years. However, two 
experimental approaches that show higher level of maturity may have the potential for 
succesful clinical translation. The first experimental approach is the “cell sheet” technology 
developed by Okano et al. in Japan(58). Its simple configuration and fabrication allows for 
the stacking of up to four hepatocyte cell sheets that can readily engraft and provide a 
defined metabolic relief to the recipient(59). This technology has already been applied 
successfully to one patient with heart failure. Other technology that shows great promise is 
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tissue and organ decellularization. Our lab and others have been able to generate several 
decellularized scaffolds for tissue engineering applications like tissue engineering of 
urethra(60), heart valves(61), blood vessel(62). More recentely, Ott et al. developed a novel 
method of perfusion decellularization that is able to generate whole organ scaffolds. The use 
of this method allowed the decellularization of a whole heart that was later repopulated 
with neonatal rat cardiomyocytes. This bioengineered heart was able to contract up to 2% of 
the normal contractile function(63). This approach may have a tremendous potential for the 
field of organ bioengineering. We have recently used a similar perfusion decellularization 
technique to liver, pancreas, intestine and kidney generating decellularized organ scaffolds 
for organ bioengineering(64, 65). These bioscaffolds preserve their tissue microarchitecture 
and an intact vascular network that can be readily used as a route for recellularization by 
perfusion of culture medium with different cell populations. In an analogous fashion, 
Uygun et al.  decellularized rat livers and repopulated them with rat primary hepatocytes, 
showing promising hepatic function and the ability of heterotopicaly transplant these 
bioengineered livers into animals for up to eight hours(66).  Baptista et al. were able to take 
this a step further by using human primary liver progenitor/stem and endothelial cells to 
bioengineer a vascularized liver. These bioengineered livers displayed some of the functions 
of a native human liver (albumin and urea secretion, drug metabolism enzyme expression, 
etc), exhibiting also an endothelialized vascular network that prevented platelet adhesion 
and aggregation, critical for blood vessel patency after transplantation(65). Nonetheless, it is 
difficult to predict the outcome and the real translational value of this technology in the present days, 
but the potential is certainly vast. Translation of it into the bioengineering of human size livers 
might help mitigate the endless hurdle of organ shortage for transplantation. 
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